



## The TIGIT/CD226 Axis Regulates Human T Cell Function

Ester Lozano, Margarita Dominguez-Villar, Vijay Kuchroo and David A. Hafler

This information is current as of August 7, 2022.

*J Immunol* 2012; 188:3869-3875; Prepublished online 16 March 2012;

doi: 10.4049/jimmunol.1103627

<http://www.jimmunol.org/content/188/8/3869>

**Supplementary Material** <http://www.jimmunol.org/content/suppl/2012/03/16/jimmunol.1103627.DC1>

**References** This article **cites 24 articles**, 8 of which you can access for free at: <http://www.jimmunol.org/content/188/8/3869.full#ref-list-1>

**Why *The JI*? Submit online.**

- **Rapid Reviews! 30 days\*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*\*average*

**Subscription** Information about subscribing to *The Journal of Immunology* is online at: <http://jimmunol.org/subscription>

**Permissions** Submit copyright permission requests at: <http://www.aai.org/About/Publications/JI/copyright.html>

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at: <http://jimmunol.org/alerts>

# The TIGIT/CD226 Axis Regulates Human T Cell Function

Ester Lozano,<sup>\*,†,‡</sup> Margarita Dominguez-Villar,<sup>\*,†,‡</sup> Vijay Kuchroo,<sup>‡,1</sup> and David A. Hafler<sup>\*,†,‡,1</sup>

T cell Ig and ITIM domain (TIGIT) is a newly identified receptor expressed on T cells that binds to CD155 on the dendritic cell surface, driving them to a more tolerogenic phenotype. Given that TIGIT contains an ITIM motif in its intracellular domain and considering the potential importance of the TIGIT/CD226 pathway in human autoimmune disease, we investigated the specific role of TIGIT in human CD4<sup>+</sup> T cells. Using an agonistic anti-TIGIT mAb, we demonstrate a direct inhibitory effect on T cell proliferation with a decrease in expression of T-bet, GATA3, IFN regulatory factor 4, and retinoic acid-related orphan receptor c with inhibition of cytokine production, predominantly IFN- $\gamma$ . Knockdown of TIGIT expression by short hairpin RNA resulted in an increase of both T-bet and IFN- $\gamma$  mRNA and protein expression with concomitant decrease in IL-10 expression. Increases in IFN- $\gamma$  with TIGIT knockdown could be overcome by blocking CD226 signaling, indicating that TIGIT exerts immunosuppressive effects by competing with CD226 for the same CD155 ligand. These data demonstrate that TIGIT can inhibit T cell functions by competing with CD226 and can also directly inhibit T cells in a T cell-intrinsic manner. Our results provide evidence for a novel role of this alternative costimulatory pathway in regulating human T cell responses associated with autoimmune disease. *The Journal of Immunology*, 2012, 188: 3869–3875.

T cells are driven into cell cycle after TCR recognition of Ag presented by MHC and a second signal first elucidated with the CD80/CD86–CD28 costimulatory pathway (1). Although this has become a major tenant in immunology, it has become clear that there are a multitude of signals integrated by the T cell ultimately leading to either entry into cell cycle, expansion, and differentiation or to nonresponsiveness or apoptosis. Curiously, many of these costimulatory pathways have multiple receptor/ligand pairs, one of which results in positive signaling events while the other transmits negative signals, such as CD28/CTLA4 (2). A first step in deciphering how T cells integrate these second signals requires an understanding of the individual components of the costimulatory pathways.

Genome-wide association scans in patients with autoimmune diseases have identified allelic variants in a number of T cell costimulatory molecular pathways as genetic risk factors for disease patho-

genesis. This includes allelic variants in the CTLA4/CD86 pathway (3–5) and CD226 that has been associated with risk to develop both type 1 diabetes and multiple sclerosis (MS) (6, 7). Costimulatory pathways regulate the functional outcome of T cell activation, and allelic variations altering the balance between positive and negative costimulatory signals may increase the risk of autoimmune diseases (2). These genetic investigations may be particularly useful in focusing on key nodal points that modulate immune response.

CD226 was first identified by Shibuya et al. (8, 9) as having a role in enhancing cytotoxic function of NK cells, demonstrating that CD226 is associated with LFA-1 to induce IFN- $\gamma$  production in naive CD4<sup>+</sup> T cells. CD226 binds to two different cell surface ligands, CD155 (poliovirus receptor) and CD112 (10, 11). T cell Ig and ITIM domain (TIGIT) is a transmembrane glycoprotein belonging to a poliovirus receptor family of type 1 proteins that also binds to CD155 and CD112 ligands (12). TIGIT is expressed on peripheral memory and regulatory CD4<sup>+</sup> T cells and NK cells and is upregulated following activation on naive CD4<sup>+</sup> T cells. CD155 is a high-affinity receptor for TIGIT expressed on monocytes and CD11c<sup>+</sup> human dendritic cells (DCs) (12). TIGIT contains an Ig-like V-type domain and an ITIM in its cytoplasmic domain, suggesting that receptor occupancy may trigger a negative signaling event. Similar to the costimulatory CD28/CTLA4–CD80/CD86 pathway where CD28 engagement induces positive and CTLA4 negative signaling while the CTLA-4/CD28 pathway has been intensively investigated, little is known regarding the TIGIT/CD226 pathway, particularly in human T cells.

Grogan and colleagues (12) described that engagement of TIGIT by CD155 on human DCs enhanced the production of IL-10 while diminishing the production of IL-12p40. In addition to effects on APCs, we demonstrated a T cell-intrinsic inhibitory effect of TIGIT-dependent T cell signaling pathway in murine models of experimental autoimmune encephalomyelitis (EAE) (13). Specifically, we demonstrated that loss of TIGIT expression in mice results in hyperproliferative T cell responses and increased susceptibility to EAE. By generating an agonistic anti-TIGIT mAb, we showed that TIGIT directly inhibited murine T cell responses even in the absence of APCs, demonstrating a T cell intrinsic inhibitory effect of TIGIT.

\*Department of Neurology, Yale School of Medicine, New Haven, CT 06520;

<sup>†</sup>Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520; and <sup>‡</sup>Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115

<sup>1</sup>V.K. and D.A.H. contributed equally to this work.

Received for publication December 15, 2011. Accepted for publication February 12, 2012.

This work was supported by National Institutes of Health Grants U19AI070352, R01NS024247, P01AI03971, and P01NS038037 (to D.A.H.). D.A.H. is a Jacob Javits Scholar of the National Institute of Neurological Disorders and Stroke. E.L. was supported by Ministerio de Educación y Ciencia/Fulbright y Cátedras "Príncipe de Asturias" 2008–2011 and is a recipient of a postdoctoral scholarship in the Beatriu de Pinós Programme (2011–2013) (Agència de Gestió d'Ajuts Universitaris i de Recerca) with the support of the Commission for Universities and Research of the Ministry of Innovation, Universities and Enterprise of the Autonomous Government of Catalonia, and the Cofund program of the Marie Curie Actions of the 7th R&D Framework Program of the European Union.

Address correspondence and reprint requests to Dr. David A. Hafler, Department of Neurology, Yale School of Medicine, 15 York Street, PO Box 208018, New Haven CT 06520-8018. E-mail address: david.hafler@yale.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: DC, dendritic cell; IRF, IFN regulatory factor; MS, multiple sclerosis; RORc, retinoic acid-related orphan receptor c; sh, short hairpin; siCD226, CD226-specific small interfering RNA; siRNA, small interfering RNA; TIGIT, T cell Ig and ITIM domain.

Copyright © 2012 by The American Association of Immunologists, Inc. 0022-1767/12/\$16.00

Considering the potential importance of the TIGIT/CD226 pathway in human autoimmune disease and based on our murine studies (13), we investigated the specific role of TIGIT in human CD4<sup>+</sup> T cell activation in the absence of APCs where CD155 expression on T cells provided a costimulatory signal. Using an agonistic anti-TIGIT mAb, we demonstrate a direct inhibitory effect on T cell proliferation with a decrease in expression of T-bet, GATA3, IFN regulatory factor (IRF)4, and retinoic acid-related orphan receptor  $\gamma$  (ROR $\gamma$ ) with inhibition of cytokine production, predominantly IFN- $\gamma$ . Knockdown of TIGIT expression by short hairpin (sh)RNA expression constructs introduced into human CD4<sup>+</sup> T cells resulted in an increase of both T-bet and IFN- $\gamma$  mRNA and protein expression. These effects could be overcome by blocking CD226 signaling, indicating that TIGIT exerts immunosuppressive effects by competing with CD226 for the same ligand CD155. Furthermore, we also show that TIGIT expression and function are not altered in untreated relapsing-remitting MS patients, suggesting that this pathway could potentially be targeted therapeutically to inhibit the hyperactivated status of memory CD4<sup>+</sup> T cells in patients. These data provide evidence for a novel role of this alternative costimulatory pathway in regulating human T cell responses associated with autoimmune disease.

## Materials and Methods

### Cell culture reagents and Abs

Peripheral venous blood was obtained from healthy control volunteers in compliance with Institutional Review Board protocols at Yale University School of Medicine. Total CD4<sup>+</sup> T cells were isolated by negative selection (CD4<sup>+</sup> T cell isolation kit II; Miltenyi Biotec, Auburn, CA) and sorted on a FACSAria (BD Biosciences, San Jose, CA).

Cells were cultured in 96-well plates in RPMI 1640 medium with 5% human AB serum (Gemini Bio-Products, Woodland, CA). The Abs used for stimulation were anti-CD3 (clone UCHT1) and anti-CD28 (clone 28.2) (BD Biosciences) at 1  $\mu$ g/ml. Recombinant human IL-2 was obtained through the AIDS Research and Reference Reagent Program (Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health) and was used at 10 U/ml.

Abs to human TIGIT (VSTM3) were provided by ZymoGenetics (a wholly-owned subsidiary of Bristol-Myers Squibb) and were generated by immunizing BALB/C mice with soluble human TIGIT protein (14). None of the five mAbs against human TIGIT was capable of blocking the binding of soluble human TIGIT to cells expressing human CD155. However, two of these mAbs showed an agonistic activity measured in T cell proliferation assays (14). For our functional assays, we use the clone 318.28.2.1 (isotype IgG1) plate-bound at 50  $\mu$ g/ml. The endotoxin level in the Ab solution was <1 EU/ml. All Abs were dialyzed before performing functional assays. Mouse Anti-TIGIT functional grade mAb (clone MBSA43) was obtained from eBioscience (San Diego, CA). Blocking anti-human CD155 (clone SKII.4) and LEAF purified mouse IgG1 isotype control were purchased from BioLegend (San Diego, CA), and blocking anti-human CD226 (clone DX11) was from Abcam (Cambridge, MA).

### Proliferation assay and apoptosis

CFSE-labeled memory T cells (10<sup>4</sup>/well) were incubated in the presence of plate-bound agonistic anti-TIGIT at 50  $\mu$ g/ml or IgG isotype control. Cells were stimulated with anti-CD3, anti-CD28, and IL-2 (10 U/ml). Fluorescence was assessed on day 5 of stimulation on a LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR). Apoptosis was measured with an FITC annexin V Apoptosis detection kit I (BD Biosciences) according to the manufacturer's instructions.

### Cell activation and intracellular staining

Cell populations were stimulated with anti-CD3, anti-CD28, and IL-2 in the presence of agonistic anti-TIGIT. At day 4, cells were restimulated with PMA (50 ng/ml) and ionomycin (250 ng/ml) for 4 h in the presence of GolgiStop (BD Biosciences). Cells were fixed and made permeable (Foxp3 staining buffer set; eBioscience) and incubated with anti-IFN- $\gamma$  (clone B27), anti-IL-13 (clone JES10-5A2), anti-IL-4 (clone 8D4-8), anti-IL-9 (clone MH9A4), and anti-IL-17 (clone BL168) from BioLegend. Staining

with a Live/Dead Fixable Dead Cell Stain Kit (Molecular Probes) was performed before fixation to allow gating on viable cells.

### ELISA

ELISA measurement of IFN- $\gamma$  and IL-10 were performed with purified coating and biotinylated detection Abs: human IFN- $\gamma$  mAb (clone 2G1) and human IFN- $\gamma$  mAb biotin-labeled (Thermo Scientific, Rockford, IL) and rat anti-human and viral IL-10 and biotin anti-human and viral IL-10 (BD Biosciences).

### Quantification of mRNA expression levels by real-time PCR

RNA was isolated using a Qiagen RNeasy Micro kit (Qiagen, Valencia, CA) and converted to cDNA by reverse transcription with random hexamers and MultiScribe reverse transcriptase (TaqMan reverse transcription reagents; Applied Biosystems, Foster City, CA). For mRNA gene expression assays, probes were purchased from Applied Biosystems and the reactions run on a 7500 Fast real-time PCR system (Applied Biosystems). To evaluate IL-2 gene expression, memory T cells were incubated in the presence of anti-TIGIT mAb or an isotype control for 2 d (probe Hs\_00914135\_m1 from Applied Biosystems). Values are represented as the difference in Ct values normalized to  $\beta_2$ -microglobulin for each sample as per the following formula: Relative RNA expression = (2<sup>- $\Delta$ Ct</sup>)  $\times$  1000.

### CD226 silencing by small interfering RNA

Pre-designed small interfering RNA (siRNA) for human CD226 and a negative control siRNA were obtained from Applied Biosystems. Purified CD4<sup>+</sup> T cells (1  $\times$  10<sup>6</sup>) were transfected with either negative control siRNA or CD226 siRNA (s20972) by electroporation, using the Nucleofector device (Amaxa). Transfected cells were incubated at 37°C for 30 min, followed by addition of 20 U/ml human IL-2 and transfer of the cells to a 96-well plate coated with anti-CD3/CD28 mAbs. On days 1 and 2 after transfection, cells were collected for RNA extraction to assess gene expression. On day 3, CD226 surface expression and IFN- $\gamma$  production were determined.

### Lentiviral shRNA knockdown of CD226 and TIGIT

Lentiviruses expressing shRNAs were obtained from the library of The RNAi Consortium (15). We initially tested five different hairpins directed against CD226 and TIGIT and compared their efficiency by real-time PCR against a control hairpin. Tested target sequences are shown in Supplemental Table I; shCD226, shTIGIT-1, and shTIGIT-2 were the most efficient.

Human CD4<sup>+</sup> T cells were plated on a 96-well plate at a concentration of 10<sup>5</sup> cells per well and activated with anti-CD3 and anti-CD28 at 1  $\mu$ g/ml. After 24 h, the medium was carefully removed, 22  $\mu$ l virus and 6  $\mu$ g/ml polybrene were added, and the plate was centrifuged at 2250 rpm for 30 min at room temperature. After centrifugation, all medium was removed and fresh supplemented RPMI 1640 medium was added. After 48 h cells were selected with 2  $\mu$ g/ml puromycin and collected for analysis 72 h after selection.


### Statistical analysis

A standard two-tailed Student *t* test was used for statistical analysis. A *p* value of <0.05 was considered statistically significant.

## Results

### TIGIT, CD155, and CD226 are upregulated on human CD4<sup>+</sup> T cells after activation

To investigate the role of TIGIT on T cell function, we began by examining TIGIT expression in human CD4<sup>+</sup> T cells *ex vivo* and after activation with anti-CD3 and anti-CD28 mAbs. As shown in Fig. 1, TIGIT was not expressed on *ex vivo* naive T cells (CD4<sup>+</sup>CD45RO<sup>-</sup>), but its expression was induced upon stimulation in the CD45RO<sup>+</sup> population. Similarly, we confirmed the upregulation of CD226 in both naive and memory populations. Interestingly, CD155, the ligand for both CD226 and TIGIT, was also induced after activation both on naive and memory T cells, although there was a higher frequency of CD155<sup>+</sup> T cells in the CD45RO<sup>-</sup> population (Fig. 1A). We confirmed upregulation of TIGIT, CD226, and CD155 gene expression by real-time RT-PCR on FACS-sorted memory T cells (Fig. 1B). The second ligand for




**FIGURE 1.** Upregulation of TIGIT, CD226, and CD155 in human CD4<sup>+</sup> T cells after activation. **(A)** Dot plots displaying the cell surface expression of TIGIT, CD226, CD155, and CD112 on naive CD4<sup>+</sup> T cells (CD45RO<sup>-</sup>) and memory T cells (CD45RO<sup>+</sup>) ex vivo and after activation with anti-CD3 and anti-CD28 for 2 d. **(B)** Kinetics of gene expression of TIGIT, CD226, and their ligands CD155 and CD112 on sorted memory T cells (CD4<sup>+</sup> CD62L<sup>+</sup> CD25<sup>low</sup> CD45RO<sup>+</sup>). Data are normalized relative to  $\beta_2$ -microglobulin. Data are representative of four donors.

CD226 and TIGIT, CD112, was not expressed on CD4<sup>+</sup> T cells ex vivo and was not upregulated upon activation.

*TIGIT signaling inhibits T cell proliferation*


Because TIGIT contains an ITIM that could trigger a negative regulation of T cell functions, we investigated whether TIGIT can also directly inhibit T cell proliferation. T cells were stimulated in the presence of an agonistic anti-TIGIT mAb (clone 318.28.2.1) for 5 d, and T cell proliferation was assessed by a CFSE dilution assay after gating on viable cells. As depicted in Fig. 2, this agonistic anti-TIGIT mAb efficiently inhibited human CD4<sup>+</sup> T cell proliferation (Fig. 2A, 2B). No significant differences were observed in frequency of viable cells (Fig. 2C, 2D). Recently, a new functional Ab against human TIGIT (clone MBSA43) has been generated; when we tested this Ab in the same conditions, we did not find an effect on T cell proliferation, although in certain conditions we observed a slight increase in IFN- $\gamma$  production (Supplemental Fig. 1). Furthermore, TIGIT ligation did not cause a significant increase in the frequency of early or late apoptotic cells (Supplemental Fig. 2). To address the mechanism by which TIGIT engagement leads to inhibition of proliferation, we evaluated the expression of cell surface markers of activation by flow cytometry. When primary CD4<sup>+</sup> T cells were cultured in the presence of the agonistic anti-TIGIT (clone 318.28.2.1), they showed decreased expression of CD25 and CD69 as compared with isotype control (Fig. 2E). To exclude the possibility that anti-TIGIT could act on the small percentage of regulatory T cells increasing suppression, we isolated CD4<sup>+</sup>CD62L<sup>+</sup>CD45RO<sup>+</sup>CD25<sup>low</sup> memory T cells by FACS sorting (Fig. 2F) and repeated proliferation assays excluding any other cell type. We confirmed that TIGIT has an intrinsic inhibitory effect on human memory T cell proliferation (Fig. 2G). To better characterize the mechanism by which TIGIT decreases T cell proliferation, we also quantified the production of IL-2 by real-time PCR. Importantly, IL-2 gene expression was significantly



**FIGURE 2.** TIGIT cell-intrinsic signaling inhibits T cell proliferation. **(A)** Proliferation of human CD4<sup>+</sup> T cells labeled with CFSE and activated with anti-CD3 and anti-CD28 with plate-bound agonistic anti-TIGIT or isotype-matched control Ab. On day 5, CFSE dilution was analyzed by flow cytometry after gating on viable cells. **(B)** Percentages of dividing cells after activation represent the CFSE<sup>low</sup> cells ( $n = 8$ ). Mean values are shown  $\pm$  SD. **(C)** Viability was assessed in all of the experiments. **(D)** No significant differences were observed in the frequency of viable cells. **(E)** Flow cytometry of the surface expression of CD25 and CD69 as markers of activation of human CD4<sup>+</sup> T cells activated in presence of agonistic anti-TIGIT or isotype control, assessed on day 5 after activation. **(F)** Sorting strategy for the purity of memory T cells (CD4<sup>+</sup>CD62L<sup>+</sup>CD25<sup>low</sup>CD45RO<sup>+</sup>). **(G)** CFSE proliferation assay of memory T cells in the presence of agonistic anti-TIGIT. Proliferation was assessed on day 5 after gating on viable cells. Percentages of proliferating cells are depicted above the histograms. **(H)** Quantitative real-time RT-PCR analysis of relative IL-2 gene expression in FACS-sorted memory T cells. Data shown are representative of four different donors. \* $p < 0.05$ .

cantly downregulated in the presence of anti-TIGIT (clone 318.28.2.1) (Fig. 2H), consistent with the decrease in TCR signaling after TIGIT ligation. Taken together, these data indicate the engagement of TIGIT by its ligands can deliver an inhibitory signal, resulting in decreased T cell activation, IL-2 production, and TCR-mediated proliferation.

Furthermore, no significant differences were found in TIGIT expression on ex vivo and activated FACS-sorted memory T cells from untreated relapsing-remitting MS patients compared with age-matched healthy donors (Supplemental Fig. 3). In agreement with the results obtained with healthy donor T cells, the inhibitory effects of TIGIT signaling are functional in T cells from MS patients, suggesting that activation of TIGIT signaling may represent a new approach for the treatment of human autoimmune disease.




**FIGURE 3.** TIGIT cell-intrinsic signaling inhibits T cell cytokine production. **(A)** Time course of the expression of transcription factors in memory T cells stimulated with IL-12 (Th1), IL-4 (Th2), TGF- $\beta$  plus IL-4 (Th9), and TGF- $\beta$  plus IL-1 $\beta$ /IL-6/IL-21 (Th17) and cultured in the presence of agonistic anti-TIGIT or isotype control for 3 d. **(B)** Intracellular cytokine staining for IFN- $\gamma$ , IL-13, IL-4, IL-9, and IL-17 in memory T cells cultured in the same conditions as in **(A)** for 4 d. Data shown are representative of at least four independent experiments.

#### TIGIT signaling inhibits cytokine production

To further study the direct mechanism of the inhibitory effect of TIGIT on T cell function, we then investigated the role of TIGIT signaling on cytokine production by CD4<sup>+</sup>CD62L<sup>+</sup>CD45RO<sup>+</sup>CD25<sup>low</sup> memory T cells. To specifically investigate whether the effect of TIGIT signaling is more prominent for a specific functional T cell subset, we incubated memory T cells with plate-bound anti-TIGIT (clone 318.28.2.1) or isotype control mAb and stimulated them in Th1, Th2, Th9, and Th17 conditions for 3 d. TIGIT ligation efficiently inhibited expression of transcription factors T-bet, GATA3, IRF4, and RORc specific for regulating Th1, Th2, Th9, and Th17 cells, respectively (Fig. 3A). We next assessed cytokine production by intracellular staining in anti-TIGIT-treated cells. Consistent with the decrease in T-bet expression, the frequency of IFN- $\gamma$ -producing T cells was significantly reduced with signaling by anti-TIGIT mAb (Fig. 3B). To a lesser extent, production of IL-13, IL-9, and IL-17 was also reduced in T cells stimulated with anti-TIGIT mAb for 4 d. These data clearly demonstrate that TIGIT suppresses T cell responses directly in a T cell-intrinsic manner.

#### CD226 knockdown decreases T-bet expression and IFN- $\gamma$ production in human CD4<sup>+</sup> T cells

In addition to the inhibitory cell-intrinsic role for TIGIT on T cells, we wanted to examine whether TIGIT has a second mechanism of negative immunoregulation by competing with CD226 for the same CD155 ligand. To specifically explore the contribution of the CD226 and TIGIT receptors, we performed an siRNA knockdown of CD226 on ex vivo CD4<sup>+</sup> T cells. A decrease in CD226 expression resulted in a decrease in T-bet and IFN- $\gamma$  mRNA expression (Fig. 4A). On day 3, we stimulated cells with PMA and ionomycin for 4 h and analyzed CD226 surface expression versus IFN- $\gamma$  production, gating on viable cells. As shown in Fig. 4B, CD226-specific small interfering RNA (siCD226) effectively re-




**FIGURE 4.** Knockdown of CD226 expression in human CD4<sup>+</sup> T cells. **(A)** CD226 gene expression in human CD4<sup>+</sup> T cells transfected with specific siCD226 or negative siRNA, assessed by real-time RT-PCR on days 1 and 2 after electroporation. **(B)** Flow cytometry of the surface expression of CD226 and IFN- $\gamma$  intracellular staining on human CD4<sup>+</sup> T cells transfected with siRNA or control, and stimulated with PMA and ionomycin for 4 h in the presence of GolgiStop. Cells were stained with a Live/Dead Fixable Dead Cell Stain Kit before fixation to allow gating on viable cells. **(C)** Measurement of IFN- $\gamma$  in the supernatants of cells transfected with siCD226 or negative siRNA. **(D)** Flow cytometry of the surface expression of CD226 and IFN- $\gamma$  intracellular staining on CD4<sup>+</sup> T cells transfected as in **(B)** and then stimulated with IL-12 for 3 d. **(E)** Flow cytometry of the surface expression of CD226 and IFN- $\gamma$  intracellular staining on human CD4<sup>+</sup> T cells transduced with shCD226 or control by lentiviral transduction. Data are representative of three independent experiments. Mean values are shown  $\pm$  SEM.

duced CD226 expression with a concomitant decrease in IFN- $\gamma$  production. We observed similar results by measuring IFN- $\gamma$  levels in the supernatants of cells transfected with siCD226 or siRNA negative (Fig. 4C). After confirming CD226 depletion, cells from replicate wells were stimulated with IL-12 for 3 more days and we observed that the decrease in CD226 expression correlates with a lower percentage of IFN- $\gamma$ -producing cells (Fig. 4D). We validated these results by lentiviral transduction of shRNA into human CD4<sup>+</sup> T cells to specifically downregulate CD226 expression. We used the vector pLKO-1, containing a gene encoding puromycin resistance, which allowed us to select T cells with stable integration of shRNA constructs. We tested five different shRNA constructs to knockdown CD226, using the target sequence indicated as shCD226, the most efficient in depleting CD226 expression (Supplemental Table I). The decrease in CD226 cell surface expression resulted in an  $\sim$ 27% reduction in IFN- $\gamma$ -producing cells (Fig. 4E). Taken together, our data strongly suggest that CD226, possibly through its interaction with CD155, can trigger a positive signal in T cells inducing T-bet expression and IFN- $\gamma$  production.

#### TIGIT knockdown increases T-bet expression and IFN- $\gamma$ production in human CD4<sup>+</sup> T cells

To better understand the role of TIGIT in this regulatory pathway, we used a specific shRNA to stably downregulate TIGIT expression in human CD4<sup>+</sup> T cells. We tested five different shRNA constructs to knockdown TIGIT; one directed against the 3' untranslated region of TIGIT mRNA (shTIGIT-1) and the other against the coding sequence (shTIGIT-2) that were efficient in downregulating TIGIT expression (Supplemental Table I). On day 3 after puromycin selection, shTIGIT-1 and shTIGIT-2 decreased the



**FIGURE 5.** Knockdown of TIGIT expression in human CD4<sup>+</sup> T cells by lentiviral transduction with two specific shRNAs. **(A)** Quantitative real-time RT-PCR analysis of relative TIGIT gene expression in human CD4<sup>+</sup> T cells infected with lentivirus containing two TIGIT-specific shRNA sequences or an empty vector, assessed on day 3 after puromycin selection. **(B)** Gene expression of other negative regulators, CTLA4 and PD-1, was measured to exclude nontarget effects. **(C)** Relative quantification of T-bet (*Tbx21*), IFN- $\gamma$ , and IL-10 mRNA in T cells transduced with shTIGIT-1, shTIGIT-2, or an empty vector. **(D)** Flow cytometry of the surface expression of TIGIT and IFN- $\gamma$  intracellular staining on human CD4<sup>+</sup> T cells infected with TIGIT-specific shRNA or control, selected with puromycin and stimulated with PMA and ionomycin for 4 h in the presence of GolgiStop. Cells were stained with a Live/Dead Fixable Dead Cell Stain Kit before fixation to allow gating on viable cells. Data are representative of four independent experiments with three individual donors. **(E)** Levels of IL-10 in the supernatants derived from the same cultures as in (C) quantified by ELISA. Mean values are shown  $\pm$  SEM.

expression of TIGIT mRNA >80% (Fig. 5A) but not of other negative T cell regulators such as CTLA4 and PD-1 (Fig. 5B).

To determine the effect of knocking down TIGIT expression on cytokine production, we examined the expression of transcription factor T-bet (*Tbx21*), the master transcription factor that induces IFN- $\gamma$  production. Knockdown of TIGIT mRNA expression was accompanied by increases in both T-bet and IFN- $\gamma$  mRNA expression (Fig. 5C). In contrast, deletion of TIGIT resulted in a significant reduction of IL-10 gene expression in cells transduced with both shTIGIT-1 and shTIGIT-2 (Fig. 5C), suggesting a central role of TIGIT in reciprocally regulating proinflammatory (IFN- $\gamma$ ) and anti-inflammatory (IL-10) cytokines.

To confirm these results at the protein level, we stimulated the puromycin-resistant cells with PMA and ionomycin for 4 h and then assayed TIGIT expression and cytokine production by intracellular staining. Consistent with a role of TIGIT in reducing T cell responses, knockdown of TIGIT increased IFN- $\gamma$  production in cells transduced with shTIGIT-1 and shTIGIT-2 (Fig. 5D), confirming that TIGIT may act directly by inhibiting IFN- $\gamma$  production in human T cells. Measurement of IL-10 secretion in transduced CD4<sup>+</sup> T cells revealed that depletion of TIGIT was accompanied by a decrease in IL-10 production (Fig. 5E), suggesting a cell-intrinsic role for TIGIT in IL-10 production in the absence of APCs.


*IFN- $\gamma$  secretion after TIGIT knockdown is mediated by CD155 engagement of CD226*

To examine the mechanism for the increased production of IFN- $\gamma$  with knockdown of TIGIT, we cultured with mAbs directed against either CD155 or CD226 that were expressed on T cells. As shown in Fig. 6, adding either anti-CD155 or anti-CD226 mAbs blocked the increased T-bet and IFN- $\gamma$  gene expression induced by TIGIT knockdown. Interestingly, blockade of CD226 or CD155 also decreased IL-10 gene expression (Fig. 6C). These data indicate that in the absence of TIGIT, CD226/CD155 interaction induces T-bet and IFN- $\gamma$  production, whereas IL-10 production requires TIGIT for its induction. These data further support our hypothesis that

CD226/CD155 provides positive costimulation to induce IFN- $\gamma$  production whereas TIGIT is required for IL-10 production.

**Discussion**

Allelic variants in the TIGIT/CD226 pathway have recently been identified as risk factors for developing human autoimmune dis-



**FIGURE 6.** Blockade of CD226 signaling with anti-CD226 or anti-CD155 decreased the effects of TIGIT knockdown. **(A)** Quantitative real-time PCR analysis of relative T-bet (*Tbx21*) expression in TIGIT-depleted CD4<sup>+</sup> T cells incubated for 4 d in the presence of increasing concentrations of plate-bound blocking anti-CD226, blocking anti-CD155, or isotype control IgG. **(B)** IFN- $\gamma$  gene expression. **(C)** IL-10 gene expression in the same conditions as in (A). Data shown are representative of four different donors.

eases (7). However, the mechanisms associated with human CD4<sup>+</sup> T cell expression of these receptors are not known. In this study, we demonstrate that engagement of TIGIT with an agonistic mAb triggers a direct inhibitory effect on T cell entry into cell cycle with a decrease in expression of the T-bet, GATA3, IRF4, and RORc transcription factors associated with inhibition of cytokine production, predominantly IFN- $\gamma$ . TIGIT expression represses T-bet, as knockdown of TIGIT induces T-bet-mediated IFN- $\gamma$  secretion while decreasing IL-10. The increase in IFN- $\gamma$  was overcome by blocking CD226 signaling, indicating that TIGIT exerts immunosuppressive effects by competing with CD226 for the CD155 ligand similar to the CD28/CTLA4 pathway. These data provide evidence for a novel role of this alternative costimulatory pathway in differentially regulating proinflammatory (IFN- $\gamma$ ) versus anti-inflammatory (IL-10) cytokine production in a T cell-intrinsic manner.

Our recent investigations in the EAE model of multiple sclerosis have demonstrated a critical role of TIGIT as a negative regulator of autoimmune responses (13). The phenotype of TIGIT-deficient mice includes augmented T cell proliferation upon immunization and higher production of proinflammatory cytokines leading to greater EAE susceptibility (13). These data in the EAE model were confirmed in a collagen-induced arthritis model of arthritis where administration of soluble TIGIT Fc-fusion protein significantly inhibited the severity of disease whereas a blocking anti-TIGIT accelerates disease development (14). Taken together, these studies show an intrinsic T cell function of TIGIT in regulating autoimmune responses and indicate a key role for the TIGIT/CD155 pathway in autoimmune diseases.

In humans, it has been reported that TIGIT expressed on T cells only exerts its immunosuppressive effects indirectly by modulating cytokine production by DCs (12). In that study, Yu et al. (12) concluded that TIGIT does not have a T cell-intrinsic function. The likely explanation for the discrepancy between their results and the present study is that the anti-TIGIT mAb (10A7) was not agonistic and perhaps recognized a different TIGIT determinant. In another study performed by Levin et al. (14), two of five anti-human TIGIT showed an agonistic effect efficiently inhibiting T cell proliferation. In our investigations, one of these clones was selected for functional assays (clone 318.28.2.1) whereas the others could bind TIGIT but did not show any agonistic effect. Consistent with data reported by Levin et al. (14), we demonstrated that engagement of TIGIT by its ligands can deliver an inhibitory signal resulting in decreased T cell activation, IL-2 production, and TCR-mediated proliferation. Thus, the agonistic function of the TIGIT mAbs *in vitro* and *in vivo* in the EAE model suggests its utility therapeutically, particularly with our recent finding of Th1 regulatory T cells in patients with MS where IFN- $\gamma$  expression inhibits the function of regulatory T cells (16).

The TIGIT-intrinsic mechanism of negative regulation of T cell functions may also have implications in tumor immunology. Similar to PD-1 ligands, TIGIT ligands CD155 and CD112 are overexpressed in certain human tumors, including colorectal carcinomas (17), gastric cancer (18), and neuroblastomas (19). CD226/CD155 interaction has been implicated as a major trigger for NK cell antitumor activity (20), whereas TIGIT/CD155 interaction inhibits NK cell cytotoxicity (21). However, the role of TIGIT in tumor settings remains to be elucidated. Our data demonstrate that TIGIT is critical for the regulation of lymphocyte function and can efficiently limit T cell-dependent immune responses. This mechanism may enable tumors overexpressing CD155 to escape from immune attack. The clinical relevance of modulation of a negative regulator to augment immune responses directed at tumors has been recently proved with the generation

of an Ab against CTLA4 (ipilimumab) that enhances immune activation against cancer cells, resulting in significant antitumor effects (22).

In this study, we demonstrated that TIGIT signaling could also directly inhibit T cell activation by a second mechanism where TIGIT acts as negative regulator by competing with CD226 for binding to its ligand CD155 to inhibit T cell responses. This new costimulatory pathway is similar to the CD28/CTLA4 pathway that binds to B7-1 (CD80) and B7-2 (CD86) ligands. Interestingly, CTLA4 interacts with at least 20-fold higher avidity than CD28 does (23). In a similar manner, TIGIT is a negative regulator that binds CD155 with higher affinity (119 nM) compared with the CD226/CD155 interaction (1–3 nM) (12). Therefore, once expressed, TIGIT can effectively compete for binding to the same CD155 ligand similar to CD28/CTLA4 interactions with B7-1/B7-2. In this regard, therapies based on interfering with the costimulatory CTLA4 pathway have recently been approved for clinical use. Specifically, a CTLA4 fusion protein (abatacept) has been approved to treat rheumatoid arthritis (24). Thus, the TIGIT/CD226 pathway is an attractive target for therapeutic manipulation.

In addition to its immunosuppressive effects on DCs, in this study we demonstrate that TIGIT exerts multiple mechanisms of peripheral tolerance: 1) the direct inhibition of T cell proliferation and production of proinflammatory cytokines; 2) induction of anti-inflammatory cytokines such as IL-10; and 3) the blockade of CD226-positive costimulatory signaling. To better understand the role of each receptor in this complex network, we performed these experiments in the absence of APCs. Given that T cells can express CD155 but not CD112, we can exclude that the observed effects are due to CD112 signaling. To dissect the underlying molecular mechanisms of this regulatory pathway, we first downregulated CD226 expression on human T cells and observed a decrease in T-bet expression and IFN- $\gamma$  production. This result is consistent with previous reports showing that introduction of mutant (Y-F322) CD226 into naive CD4<sup>+</sup> T cells suppresses their growth initiated by CD3 and LFA-1 ligations in the absence of IL-2, suggesting that CD226 functions as a signal transducer of LFA-1 upon triggering T cell activation (9). When we specifically knocked down TIGIT expression, we obtained the opposite results: an increase in T-bet and IFN- $\gamma$  expression, consistent with the inhibitory effects triggered by the agonistic anti-TIGIT mAb. These data demonstrate that TIGIT ligation initiates a negative signaling cascade and by blocking CD226 or CD155 in TIGIT-depleted cells, and the increases in IFN- $\gamma$  production are due to an enhanced CD226/CD155 interaction.

Interestingly, lack of TIGIT resulted in a decrease in IL-10 production. Accordingly, studies in TIGIT<sup>-/-</sup> mice showed that IL-10 was not induced by Ag-specific stimulation in TIGIT<sup>-/-</sup> T cell cultures, suggesting that production of IL-10 by T cells was impaired (13). One possible explanation for this defect in IL-10 production could be that TIGIT signaling directly activates IL-10 production but agonistic anti-TIGIT mAb failed to increase IL-10 expression (data not shown). Alternatively, in the absence of TIGIT, CD226 can interact with CD155, increasing IFN- $\gamma$  while repressing IL-10 gene expression. However, blocking CD226/CD155 interaction did not increase IL-10 expression. It has been reported that TIGIT, through its interaction with CD155, can modulate Erk activity and increase IL-10 production by DCs (12). It is intriguing to speculate that T cells expressing CD155 might be regulated in a similar manner and thus TIGIT depletion impaired IL-10 production by CD155-expressing T cells.

TIGIT/CD226 pathway is a novel regulatory pathway of T cell function associated with human autoimmune disease. Manipula-

tion of the TIGIT/CD226 axis in vitro regulated T cell function by cell-intrinsic and cell-extrinsic mechanisms. To examine the potential therapeutic intervention of this pathway in patients with autoimmune diseases, we demonstrate that TIGIT expression is not altered in untreated relapsing-remitting MS patients and that an agonistic Ab to TIGIT has an inhibitory effect on CD4<sup>+</sup> T cells from MS patients. Although further studies are needed to test the therapeutic benefits of targeting inhibitory pathways, modulation of the TIGIT/CD226 axis may allow more targeted manipulation of human CD4<sup>+</sup> T cells in autoimmune diseases.

## Acknowledgments

We thank the blood donors and MS patients for participation. Abs to human TIGIT were provided by ZymoGenetics/Bristol-Myers Squibb under a Material Transfer Agreement.

## Disclosures

The authors have no financial conflicts of interest.

## References

- Sharpe, A. H. 2009. Mechanisms of costimulation. *Immunol. Rev.* 229: 5–11.
- Vijayakrishnan, L., J. M. Slavik, Z. Illés, R. J. Greenwald, D. Rainbow, B. Greve, L. B. Peterson, D. A. Hafler, G. J. Freeman, A. H. Sharpe, et al. 2004. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. *Immunity* 20: 563–575.
- International Multiple Sclerosis Genetics Consortium and The Wellcome Trust Case Control Consortium 2. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature* 476: 214–219.
- Maier, L. M., and D. A. Hafler. 2009. Autoimmunity risk alleles in costimulation pathways. *Immunol. Rev.* 229: 322–336.
- Ueda, H., J. M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D. B. Rainbow, K. M. Hunter, A. N. Smith, G. Di Genova, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature* 423: 506–511.
- Hafler, J. P., L. M. Maier, J. D. Cooper, V. Plagnol, A. Hinks, M. J. Simmonds, H. E. Stevens, N. M. Walker, B. Healy, J. M. Howson, et al. 2009. CD226 Gly307Ser association with multiple autoimmune diseases. *Genes Immun.* 10: 5–10.
- International Multiple Sclerosis Genetics Consortium 2009. The expanding genetic overlap between multiple sclerosis and type I diabetes. *Genes Immun.* 10: 11–14.
- Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, T. McClanahan, T. Kitamura, J. Nicholl, G. R. Sutherland, L. L. Lanier, and J. H. Phillips. 1996. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. *Immunity* 4: 573–581.
- Shibuya, K., J. Shirakawa, T. Kameyama, S. Honda, S. Tahara-Hanaoka, A. Miyamoto, M. Onodera, T. Sumida, H. Nakauchi, H. Miyoshi, and A. Shibuya. 2003. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. *J. Exp. Med.* 198: 1829–1839.
- Bottino, C., R. Castriconi, D. Pende, P. Rivera, M. Nanni, B. Carnemolla, C. Cantoni, J. Grassi, S. Marcenaro, N. Reymond, et al. 2003. Identification of PVRL2 (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. *J. Exp. Med.* 198: 557–567.
- Tahara-Hanaoka, S., K. Shibuya, Y. Onoda, H. Zhang, S. Yamazaki, A. Miyamoto, S. Honda, L. L. Lanier, and A. Shibuya. 2004. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVRL2 (CD155) and nectin-2 (PRR-2/CD112). *Int. Immunol.* 16: 533–538.
- Yu, X., K. Harden, L. C. Gonzalez, M. Francesco, E. Chiang, B. Irving, I. Tom, S. Ivelja, C. J. Refino, H. Clark, et al. 2009. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. *Nat. Immunol.* 10: 48–57.
- Joller, N., J. P. Hafler, B. Brynedal, N. Kassam, S. Spoerl, S. D. Levin, A. H. Sharpe, and V. K. Kuchroo. 2011. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. *J. Immunol.* 186: 1338–1342.
- Levin, S. D., D. W. Taft, C. S. Brandt, C. Bucher, E. D. Howard, E. M. Chadwick, J. Johnston, A. Hammond, K. Bontadelli, D. Ardourel, et al. 2011. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. *Eur. J. Immunol.* 41: 902–915.
- Moffat, J., D. A. Grueneberg, X. Yang, S. Y. Kim, A. M. Kloepper, G. Hinkle, B. Piquani, T. M. Eisenhaure, B. Luo, J. K. Grenier, et al. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. *Cell* 124: 1283–1298.
- Dominguez-Villar, M., C. M. Baecher-Allan, and D. A. Hafler. 2011. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. *Nat. Med.* 17: 673–675.
- Masson, D., A. Jarry, B. Baur, P. Blanchardie, C. Labois, P. Lustenberger, and M. G. Denis. 2001. Overexpression of the CD155 gene in human colorectal carcinoma. *Gut* 49: 236–240.
- Tahara-Hanaoka, S., K. Shibuya, H. Kai, A. Miyamoto, Y. Morikawa, N. Ohkouchi, S. Honda, and A. Shibuya. 2006. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. *Blood* 107: 1491–1496.
- Castriconi, R., A. Dondero, M. V. Corrias, E. Lanino, D. Pende, L. Moretta, C. Bottino, and A. Moretta. 2004. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. *Cancer Res.* 64: 9180–9184.
- Chan, C. J., D. M. Andrews, N. M. McLaughlin, H. Yagita, S. Gilfillan, M. Colonna, and M. J. Smyth. 2010. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. *J. Immunol.* 184: 902–911.
- Stanietsky, N., H. Simic, J. Arapovic, A. Toporik, O. Levy, A. Novik, Z. Levine, M. Beiman, L. Dassa, H. Achdout, et al. 2009. The interaction of TIGIT with PVRL2 and PVRL1 inhibits human NK cell cytotoxicity. *Proc. Natl. Acad. Sci. USA* 106: 17858–17863.
- Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.* 363: 711–723.
- Collins, A. V., D. W. Brodie, R. J. Gilbert, A. Iaboni, R. Manso-Sancho, B. Walse, D. I. Stuart, P. A. van der Merwe, and S. J. Davis. 2002. The interaction properties of costimulatory molecules revisited. *Immunity* 17: 201–210.
- Kremer, J. M., R. Westhovens, M. Leon, E. Di Giorgio, R. Alten, S. Steinfeld, A. Russell, M. Dougados, P. Emery, I. F. Nuamah, et al. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. *N. Engl. J. Med.* 349: 1907–1915.